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Abstract
Primary hyperparathyroidism is the most frequent manifestation of multiple endocrine 
neoplasia type 1 (MEN1) syndrome. Bone and renal complications are common. Surgery 
is the treatment of choice, but the best timing for surgery is controversial and predictors 
of persistence and recurrence are not well known. Our study describes the clinical 
characteristics and the surgical outcomes, after surgery and in the long term, of the 
patients with MEN1 and primary hyperparathyroidism included in the Spanish Registry 
of Multiple Endocrine Neoplasia, Pheochromocytomas and Paragangliomas (REGMEN). 
Eighty-nine patients (49 men and 40 women, 34.2 ± 13 years old) were included. Sixty-
four out of the 89 underwent surgery: a total parathyroidectomy was done in 13 patients, 
a subtotal parathyroidectomy in 34 and a less than subtotal parathyroidectomy in 15. 
Remission rates were higher after a total or a subtotal parathyroidectomy than after a less 
than subtotal (3/4 and 20/22 vs 7/12, P < 0.05), without significant differences in permanent 
hypoparathyroidism (1/5, 9/23 and 0/11, N.S.). After a median follow-up of 111 months, 
20 of the 41 operated patients with long-term follow-up had persistent or recurrent 
hyperparathyroidism. We did not find differences in disease-free survival rates between 
different techniques, patients with or without permanent hypoparathyroidism and patients 
with different mutated exons, but a second surgery was more frequent after a less than 
subtotal parathyroidectomy.
Introduction
Multiple endocrine neoplasia type 1 (MEN1) syndrome 
is a rare hereditary disease, with an estimated prevalence 
of 0.15–0.30 cases per 1000 in general population (1, 2). 
Primary hyperparathyroidism (PHPT) is its most common 
manifestation: most carriers of a MEN1 mutation will 
have developed PHPT by age 50 years. It is also the first 
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clinical manifestation, usually diagnosed before 30 years 
of age, and bone and renal complications are common. 
However, not many clinical studies about this specific 
type of PHPT have been published in recent years. Total 
parathyroidectomy (TPTX) with autotransplantation 
of parathyroid tissue in a forearm muscle or subtotal 
parathyroidectomy (SPTX) is the treatment of choice. 
A simultaneous transcervical thymectomy is also 
recommended, to remove a putative intrathymic 
parathyroid gland and to prevent the development of a 
subsequent thymic carcinoid tumor. Controversies persist 
regarding the role of presurgical localization studies or 
the ideal timing for surgery, both at initial diagnosis and 
at recurrence. Hyperplasia affecting all the parathyroid 
tissue is the most common pathological finding, making 
recurrences much more frequent than in sporadic 
hyperparathyroidism, so PHPT often represents an active 
disease for many years in a patient’s lifespan (1, 2, 3, 4, 5).
The aim of this study was to describe the clinical 
characteristics, diagnostic studies, treatment and follow-up 
of all the patients with MEN1 and PHPT included in the 
REGMEN (the Spanish Registry of Multiple Endocrine 
Neoplasia, Pheochromocytmas and Paragangliomas (PPGL)).
Patients and methods
The REGMEN is a collaborative and multicentric project 
designed by the Spanish Group for the Study of MEN 
and PPGL. The registry is an online database designed to 
collect extensive clinical information about patients with 
MEN1, MEN2A, MEN2B, and PPGL, both prospectively 
and retrospectively. It has been approved by the Ethical 
Committee of the Principado de Asturias. Informed 
consent was obtained from all patients prior to their 
inclusion in the registry.
Demographics, symptoms at diagnosis, biochemical 
and densitometric parameters and imaging studies were 
obtained from the medical records, as well as treatments 
and their results.
The diagnosis of PHPT was made in the presence 
of hypercalcemia and non-suppressed PTH or 
normocalcemic hyperparathyroidism (high PTH, 
normocalcemia, excluding other causes for secondary 
hyperparathyroidism). Bone mineral density (BMD) 
was assessed using dual-energy X-ray absorptiometry. 
Osteoporosis was established when the T score at any 
studied bone site was under −2.5, and osteopenia when T 
score was under −1 (6). Z score was not analyzed since it 
had been registered in a very small number of cases.
Patients were considered to have a TPTX if all 
identified parathyroid glands were removed, usually 
with autotransplantation of parathyroid tissue into the 
nondominant forearm or the neck, and a SPTX if three or 
more parathyroid glands were removed, leaving one or a 
partial gland behind. Any lesser resection was considered 
less than SPTX (<SPTX). Criteria for persistency and 
recurrence were the same as for initial diagnosis. A 
recurrence was diagnosed when PHPT recurred after at 
least 6 months of normal calcium and PTH. Permanent 
hypoparathyroidism was defined as lasting for more than 
6 months.
Statistical analysis
For the analysis, categorical variables were summarized as 
frequency counts and percentages. Continuous variables 
were summarized as the mean + standard deviation when 
normal and as the median and range or interquartile 
range (IR) when not normal, unless otherwise specified. 
The normal distribution of the quantitative variables was 
verified or excluded using the Kolmogorov–Smirnov test 
for normality. Some parameters analyzed in different 
time points followed the normal distribution at some 
points, but not at others, and are therefore presented as 
median and range or IR. Chi-square and Fisher’s exact 
test in case of categorical variables and Student t-test or 
Mann–Whitney U test for quantitative variables were 
used for comparisons. The relation between categorical 
variables (surgical technique, presence or absence of 
hypoparathryroidism and mutated exon) and persistent/
recurrent PHPT was analyzed using Kaplan–Meier survival 
analysis and the log-rank test. To evaluate changes in 
medical practices or results over time, patients were 
grouped together by their decade of diagnosis. IBM SPSS 
Statistics, version 22 was used for data analysis.
Results
Baseline patients’ characteristics
Among the 112 patients with MEN1 mutation from 39 
different families registered in REGMEN, 94 had been 
diagnosed with PHPT. Five patients were excluded due 
to significant missing information. The remaining 89 
patients were included in the analysis. They were 49 men 
and 40 women with a mean age at diagnosis of PHPT of 
34.2 ± 13 years and had been diagnosed between 1979 
and 2015 in 17 Spanish hospitals. Twenty-one of them 
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were the index case in their family, while 34 had been 
diagnosed through biochemical screening and 27 through 
genetic screening; information about the other seven was 
missing. Higher prevalence of genetic screening in more 
recent years was not observed. Genetic testing had been 
done in 87 patients and a mutation had been found in 
all but four of them. Exon 10 was the most commonly 
affected (45 cases), but a single family was responsible for 
20 of the 45 cases; exon 3 (11 patients), exon 2 (9 patients) 
and exon 7 (5 patients) were also commonly affected, but 
mutations in exons 4, 5, 6 and 9 were also found. Four 
members of one family had impaired splicing due to an 
intronic mutation.
Fifty patients were asymptomatic at diagnosis, 29 
patients had developed kidney stones, gastrointestinal 
symptoms were present in eight patients, bone symptoms 
in three and neuromuscular symptoms in one. Age at 
diagnosis and sex were similar between symptomatic 
and asymptomatic patients (32.6 ± 13.6 vs 36.5 ± 12, 
N.S.; 30/50 women vs 19/39, N.S.). Symptoms were 
more frequent in index cases than in patients diagnosed 
through biochemical or genetic screening (19/27 vs 12/34 
and 8/27 respectively, P = 0.026), even if the age was 
similar in the three groups.
Biochemical parameters at diagnosis are summarized 
in Table 1. Serum PTH levels were moderately associated 
with serum calcium levels (r = 0.42, P = 0.002). PTH, but 
not calcium, correlated with age (r = 0.40, P = 0.002). 
Patients with nephrolithiasis had higher PTH (median 
15.3, IR 11.8–19.9 vs 8.9, IR 6.8–12.2 pmol/L, P = 0.001), 
but age and calcium were not different from patients 
without nephrolithiasis. Renal function was normal in 
every patient.
BMD was measured before surgery in thirty-three 
patients, that were not older than the whole cohort 
nor were diagnosed more recently, and it was classified 
as osteopenia in 8 and as osteoporosis in 11, without 
differences between men and women. Patients with 
osteoporosis were significantly older than those with 
osteopenia or normal bone mass (42.8 ± 18.3 vs 36.4 ± 9 
and 28 ± 10 years respectively, P = 0.028). No correlation 
was found between calcium and PTH levels and bone 
mass, even if there was a non-significant trend to 
higher PTH values in those with worse bone mass (9, 
10.1 and 14.1 pmol/L in normal bone mass, osteopenia 
and osteoporosis respectively). Only two bone fractures 
were registered at presentation: a vertebral fracture in a 
25-year-old man and a distal radius fracture in a 50-year-
old woman.
Forty-eight had at least one localization study and 
thirty-three had at least two (Table 1).
Surgical treatment
Sixty-four patients had undergone parathyroid surgery. 
Presurgical biochemical parameters are summarized 
in Table 2. Surgery was recommended because of the 
patient’s age in 39 patients, due to renal involvement in 
22 patients, due to symptomatic hyperparathyroidism 
in 10 patients, due to bone involvement in 10 patients 
and because of the degree of hypercalcemia in 2 patients: 
more than one reason were registered in several patients.
The first surgical intervention took place between 
1981 and 2014, in the first year after the diagnosis of PHPT 
in 39 patients and after a median of 26 months in the 
other 25 (range 13–265 months). Patients with delayed 
Table 1 Clinical, biochemical and densitometric parameters and localization studies at diagnosis. Frequency counts, mean and 
standard deviation or median and range are presented. Densitometric parameters were available for 33 patients. The number of 
patients that underwent each localization technique, as well as the number that were positive are presented.
Parameter Value
Women/men 40/49
Age at diagnosis (years) 34.2 ± 13
Serum calcium (mmol/L) 2.75 (2.64–2.89)
PTH (pmol/L) 9.8 (7.6–15.1)
24-h urine calcium (mmol/24 h) 8.78 (6.08–10.48)
Creatinine (µmol/L) 70.7 (58.3–79.6)
Lumbar spine T score −0.04 (−1.62 to 0.51)
Femoral neck T score 0.06 (−1.96 to 0.56)
Normal bone mass/osteopenia/osteoporosis 14/8/11
Scintigraphy 45 34 positive
Ultrasonography 30 16 positive
SPECT-CT 6 5 positive
Computed tomography 4 2 positive
Magnetic resonance imaging 6 5 positive
This work is licensed under a Creative Commons 
Attribution-NonCommercial 4.0 International License.https://doi.org/10.1530/EC-19-0321
https://ec.bioscientifica.com © 2019 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 06/17/2020 07:14:49AM
via free access





surgery had lower calcium and PTH levels at diagnosis 
(2.72 ± 0.12 vs 2.97 ± 0.3 mmol/L, P = 0.026, and 10.4 ± 3.6 
vs 20.4 ± 20.5 pmol/L, P = 0.028), but they raised over time 
and presurgical values were not different between patients 
with early and delayed surgery. Patients with delayed 
surgery were less symptomatic at diagnosis (8/25 vs 25/39, 
P = 0.012), but no differences were found in calcium 
urinary excretion or renal function, age, sex, type of 
diagnosis, BMD, surgical technique or surgical outcome. 
Nephrolithiasis was less prevalent (6/25 vs 18/39), but the 
difference did not reach statistical significance (P = 0.07).
A SPTX was the most common procedure (thirty-
four patients), with autotransplantation in five of them. 
A TPTX was done in 13 patients, with autotransplantation 
in 10. No information about the surgical technique was 
available for two patients. The remainder 15 patients had 
a <SPTX. A transcervical thymectomy was performed in 
19 patients. Surgical technique did not correlate with 
the results of localization studies nor with the decade 
of surgery (Table 3). An ectopic parathyroid gland was 
described in two patients.
Parathyroid hyperplasia was described by the 
pathologist in 47 cases, one or more parathyroid adenomas 
in 19 cases, and normal parathyroid glands in 10. Eleven 
patients had more than one pathological diagnosis. 
Pathological reports were missing for five patients.
Postsurgical evaluation was available in 38 patients: 
eight of them had persistent hyperparathyroidism and 
ten permanent hypoparathyroidism (Table 2). TPTX and 
SPTX were equally effective achieving remission, and 
both were superior to <SPTX (P = 0.009). No significant 
difference was found in hypoparathyroidism rates, even 
though no cases were diagnosed in the patients with 
<SPTX. Age at diagnosis, sex, presurgical calcium and PTH 
levels, thymectomy, and histology were not significant 
prognostic factors for remission. Surgical outcome in 
relation to mutated exon is presented in Table 4.
Long-term follow-up
Long-term postsurgical follow-up was available for 
41 patients. After a median follow-up of 111 months, 
persistent or recurrent PHPT was found in 20 patients: 
Table 2 Presurgical clinical data (or data at diagnosis for non-operated patients) and surgical outcomes in patients undergoing 
surgery with different techniques. The data from the two patients with no information about the surgical technique are not 
included. Data are presented as mean (age), median (all other quantitative parameters) or as frequency counts of available data 
(persistence, hypoparathyroidism, recurrence and reoperations). Follow-up is considered from surgery to the last follow-up visit in 
operated patients and from diagnosis in non-operated patients. Only patients with long-term follow-up are considered for 
recurrence and permanent hypoparathyroidism analysis.
No surgery <SPTX SPTX TPTX Total
No. of patients 25 15 34 13 89
Men/women 9/16 9/6 14/20 7/6 49/40
Age at diagnosis 34.3 35.2 32.2 38.2 34.3
Age at 1st surgery – 35.9 34.4 38.1 35.5
Presurg calcium (mmol/L) 2.69 2.75 2.84 2.50 2.75
Presurg PTH (pmol/L) 8.2 12.5 9.8 6.9 9.8
Follow-up (months) 146 108 84 204 116
Persistence – 5/12a 2/22 1/4 8/38
Hypoparat – 0/11 9/23 1/5 10/39
Persistence + recurrence – 7/11 12/23 1/6 20/41
Reoperation – 4/11 3/23 0/6 6/41
hypoparat, permanent hypoparathyroidism; presurg, presurgical; <SPTX, less than subtotal parathyroidectomy; SPTX, subtotal parathyroidectomy; TPTX, 
total parathyroidectomy.
aP < 0.05 when compared to SPTX and TPTX.
Table 3 Surgical techniques throughout the decades covered 
by the study: the differences were not statistically significant.
Decade Number of patients Surgical technique




1990–1999 11 2 <SPTX
4 SPTX
5 TPTX




2010–2015 16 4 <SPTX
9 SPTX
3 TPTX
<SPTX, less than subtotal parathyroidectomy; SPTX, subtotal 
parathyroidectomy; TPTX, total parathyroidectomy.
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7/11 after <SPTX, 12/23 after SPTX and 1/6 after TPTX. 
A patient with unknown surgical technique did not 
recur. Kaplan–Meier estimates of disease-free survival 
did not reveal differences among surgical techniques 
(Fig. 1A), between patients with and without permanent 
hypoparathyroidism (Fig. 1B) or patients with different 
mutated exons (data not shown). However, when 
analyzing the probability of having a second surgery, 
the risk was higher in patients with a <SPTX at their first 
surgery (Fig. 2).
Seventeen patients had a second surgery 92 months 
(median) after the first one (range 9–251; 78.5 after 
<SPTX, 105 after SPTX and 91.8 after TPX, N.S.): six 
because of persistent hypercalcemia and six recurrences 
(two of them after a long time in hypoparathyroidism); 
no clinical information between surgeries was available 
for five patients. Severe hypercalcemia was not found in 
any patient. Eight of them had had a SPTX, six a <SPTX, 
two a TPTX, and the surgical technique was missing in 
one. Autotransplantation was decided for six patients. 
A transcervical thymectomy was done in 7 of the 15 
patients without it. Postsurgical evaluation was available 
for 12 of the 17 patients: hyperparathyroidism persisted 
in 3, and permanent hypoparathyroidism developed in 
5 patients (5/12 vs 10/39 in the first intervention, N.S.). 
Two patients had a third surgery because of persistent 
hypercalcemia: one was a failed exploration of 
the arm implant and the other a successful total 
thyroidectomy.
No follow-up after diagnosis was available for 11 
patients. In the last follow-up visit, 14 patients with PHPT 
had not been operated, after a median follow-up since 
diagnosis of 147 months (47–302). They were 43.4 ± 18.5 
years old, median serum calcium was 2.69 mmol/L 
(2.42–3.24) and serum PTH was 9.9 pmol/L (4–30.5). The 
41 operated patients with follow-up (median 111 months, 
range 2–392) were 48.9 ± 12 years old at their last visit, 
their serum calcium was 2.45 mmol/L (1.4–2.77) and 
their PTH 7.2 pmol/L (0.3–16.2). Five patients suffered 
permanent hypoparathyroidism. Seven patients died 
during follow-up (Table 5).
Discussion
Clinical registries of rare diseases allow to collect 
information from a high number of patients gathering 
data from different hospitals in real practice. The aim of 
our project is to improve our knowledge about this disease, 
its manifestations in the long term, our current clinical 
practice and the outcomes of surgery. The multicentric 
participation in the registry allows a generalization of 
our findings to the real situation of MEN1 patients in 
our country: even if most participating centers were 
Table 4 Surgical outcomes in the 57 operated patients harboring mutations in different exons of the MEN1 gene (P < 0.001 for 
chi-square test analysis of the whole table; paired comparisons were not done due to the small number of cases in each 
category). Genetic study revealed an intronic mutation in four members of the same family, no mutation was found in two 
patients and no genetic study was available for one more patient.
Exon 2 Exon 3 Exon 4 Exon 5 Exon 6 Exon 7 Exon 9 Exon 10
Persistence 4 0 1 0 0 0 0 3
Remission 2 3 0 0 3 4 0 15
Unknown 2 3 0 1 1 0 3 12
Figure 1
Kaplan–Meier estimates of disease-free survival 
after surgery for PHPT in MEN1 patients. 
Follow-up is displayed in months. No significant 
differences were found when comparing different 
surgical techniques (A) or patients with or without 
permanent hypoparathryroidism (B).
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university tertiary hospitals, those are where most MEN1 
patients are cared for. An inclusion bias is unlikely since 
most participating centers have included all their MEN1 
patients.
Our series is similar to others in the equal incidence 
in both sexes and a mean age at diagnosis in the thirties 
(7, 8, 9, 10, 11). However, a significant number (15) of 
patients were diagnosed over the age of 50 years, most 
of them as parents of an index case, or less commonly 
after a parathyroidectomy for a suspected sporadic PHPT. 
Unlike other series (12), index patients were not older 
than patients diagnosed through biochemical or genetic 
screening.
Clinical presentation was often mild or asymptomatic, 
with mild elevations of serum calcium and PTH in 
all the patients both at diagnosis and at recurrences, 
but nephrolithiasis had been diagnosed in 32.6%, 
and osteoporosis in 33% of those undergoing a bone 
densitometry. The prevalence of nephrolithiasis is lower 
compared to other series (13, 14), probably because we 
registered its prevalence at diagnosis and others have 
registered the prevalence in their whole MEN1 population. 
Prevalence of bone loss has been studied in heterogeneous 
groups in relation to age and PHPT duration and using 
very different criteria (T score lower than −2 or −2.5, Z 
score lower than −2), leading to a wide variability in low 
bone mass rates, from 17 to 47% (14, 15, 16, 17): our 
results do not differ significantly from those figures. As 
expected, osteoporosis risk increased with aging. Serum 
calcium did not correlate with the severity of clinical 
presentation, but serum PTH was higher in patients with 
nephrolithiasis and there was also a non-significant trend 
to higher PTH values in those with worse bone mass.
Presurgical localization studies were done in 
more than half of our patients, even if they are not 
recommended in MEN1 syndrome for deciding about the 
surgical technique (2, 18, 19), and they seldom identify 
all parathyroid tissue, including supernumerary glands. 
As a matter of fact, many patients underwent SPTX or 
TPTX independently of the imaging findings. However, 
their utilization may be justified as a useful tool for the 
presurgical identification of ectopic or supernumerary 
glands before reintervention.
Sixty-four out of our 89 patients had at least one 
parathyroidectomy, a similar proportion compared to 
the French and Belgian MEN1 registry (7). Information 
about surgery indication rates in other countries is scarce 
since many studies include only operated patients. Since 
the best timing for parathyroid surgery in MEN1 remains 
unknown (1, 2, 18), more studies are needed analyzing 
long-term development of complications in treated and 
untreated patients, or comparing patients with early versus 
delayed surgery. Early surgery may prevent bone and 
renal damage, but parathyroid identification at surgery is 
more difficult due to smaller size (18). It may also entail 
a higher probability of needing a second surgery through 
the lifespan, since recurrence rates increase in relation to 
the follow-up time: reintervention is more challenging 
because of postoperative fibrosis, leading to worse results 
and a higher risk of complications. Our contribution in 
this area is limited: some patients were operated on just 
after diagnosis, while others had surgery many years 
after. We could only identify the presence of symptoms 
and higher levels of calcium and PTH as factors leading 
to earlier surgery, so probably much of this variability in 
Figure 2
Kaplan–Meier estimates of reintervention-free survival after surgery for 
PHPT in MEN1 patients. Follow-up is displayed in months. The risk for a 
second surgery is higher for patients who had a less than subtotal 
parathyroidectomy (<SPTX) at their first surgery (P = 0.034).
Table 5 Causes of death during follow-up and time to death 






Surgical complication 1 10
Gastroenteropancreatic tumor 3 40–177–208
Adrenocortical carcinoma 1 205
Metastatic adenocarcinoma 1 62
Acute pancreatitis 1 55
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clinical practice is due to different criteria of the treating 
physicians, in the absence of evidence-based guidelines. 
Some non-operated patients had stable calcium levels in 
the high-normal range for many years and did not develop 
complications, but the small number of cases hinders any 
solid conclusion. Longitudinal studies are still needed to 
establish the best timing for parathyroidectomy.
Current guidelines agree that parathyroid surgery is 
the elective treatment for PHPT in patients with MEN1 
and that SPTX, leaving a viable 30- to 50-mg remnant 
from the most normal-appearing gland, or TPTX with 
autotransplantation, in combination with transcervical 
thymectomy, are the procedures of choice (2, 4, 5, 7, 10, 
11, 19). Parathyroid surgery in the context of MEN1 is 
more challenging compared to sporadic PHPT, due to 
higher risk of persistent and recurrent disease and higher 
complications rates. Our results support these statements: 
postsurgical remission rates were significantly higher with 
SPTX or TPTX than with <SPTX. However, at least four 
patients in the <SPTX were index cases and underwent 
surgery before the diagnosis of MEN1, with persistence 
of hypercalcemia in three of them and recurrence after 
initial remission in the other one: three of them had a 
second surgery. Surgical prognosis is undoubtedly worse 
in this situation, and efforts should be made to avoid a 
delay of the diagnosis of MEN1 in young patients with 
PHPT. The lower rate of hypoparathyroidism after <SPTX 
did not reach statistical significance, probably due to 
the small number of patients in each category. We could 
not statistically prove the differences in recurrence-free 
survival after different surgical techniques, in contrast with 
other studies (8, 10, 11, 20, 21); the reduced percentage 
(64%) of operated patients with complete follow-up data 
may have contributed to this unexpected negative result. 
However, the risk for a second surgery was higher after 
<SPTX, suggesting a more severe disease at recurrence in 
this group or a higher predisposition for reintervention 
among physicians when they know that an incomplete 
surgery has been done in the first attempt. Postsurgical 
hypoparathyroidism was not associated with a lower 
risk of recurrence, as opposed to the results of another 
series (11). In recent years unilateral clearance, a specific 
form of minimally invasive parathyroidectomy, has 
been proposed (22, 23): patients with a single abnormal 
parathyroid gland in presurgical imaging studies undergo 
excision of the abnormal gland, followed by excising the 
ipsilateral gland as well as the ipsilateral cervical thymus. 
In case of recurrence, a second surgery can be confined to 
the contralateral neck, a virgin operative field, preventing 
fibrosis and therefore minimizing the probability of 
recurrent laryngeal nerve damage and other surgical 
complications. Two small cohorts of six and eight patients 
respectively have shown remission rates comparable to 
standard surgery with lower rates of hypoparathyroidism 
(22, 23), but larger series and longer follow-up are needed. 
We cannot contribute to evaluate this technique since it 
was not the standard practice in our country in the years 
covered by the registry.
Age at PHPT diagnosis, sex, presurgical calcium 
and PTH levels, thymectomy, and histology were not 
significant prognostic factors for persistent disease. The 
Dutch MEN1 Registry found lower presurgical calcium 
levels in patients that required a second surgery during 
follow-up (10), but this finding has not been confirmed by 
others and can be related to the concept that more severe 
forms of PHPT have higher surgical success.
We investigated if different genotypes could help 
to predict surgical outcomes. Previous studies did not 
find genotype–phenotype correlation in relation to 
clinical presentation or severity (8, 24, 25), but one study 
including 73 patients with MEN1 and surgically treated 
PHPT found a significantly lower risk of persistence and 
recurrence after <SPTX, but not after SPTX/TPTX, in 
patients with nonsense or frameshift mutations in exons 
2, 9, and 10 when compared with patients with other 
mutations (10). Another study found that mutations 
in exon 3 were associated with worse recurrence rates; 
however, all patients with mutations in exon 3 had been 
initially operated with <SPTX (11). Based on these previous 
reports we analyzed our data: early postsurgical results 
were significantly different depending on the mutated 
exon, with remission in all patients carrying mutations 
in exons 3, 6 and 7, but numbers in each category were 
small. We did not find a significantly different recurrence-
free survival in patients harboring mutations in exons 2, 
9 and 10, nor in patients with mutations in exon 3, nor in 
patients with mutations in exon 10 (the most frequently 
mutated exon in our series). Small numbers of patients 
in each group may have hindered the discovery of more 
significant associations. Our data, therefore, do not 
confirm previous findings in relation with a prognostic 
value of particular genotypes.
Long-term postsurgical hypoparathyroidism is not 
always irreversible in the case of MEN1 patients, since 
very small parathyroid remnants can grow and be able to 
secrete normal or excessive amounts of PTH. Among our 
ten patients with permanent hypoparathyroidism two 
required a second parathyroid surgery (28 and 124 months 
after the first one) and only two required treatment 
for hypoparathyroidism at their last follow-up visit. 
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Other groups have outlined this phenomenon before 
(10, 11). Since overtreatment of hypoparathyroidism 
is not harmless (26), tapering calcium and vitamin D 
supplements can be required in some patients even many 
years after surgery.
Our study had several limitations. As a registry-based 
study, it was retrospective and spanned many years: 
current guidelines were not followed in some patients, 
because they were diagnosed and treated before these 
guidelines were written. Despite the active collaboration 
of many of the MEN group members in the collection of 
missing data, some relevant information was lacking due 
to variability in clinical practice, incomplete follow-up, or 
medical assistance in different hospitals throughout the 
patients’ life. Therefore, postsurgical data of past surgeries 
were not available for some patients and, for others, we 
could not obtain confident information about the long-
term development of bone and renal complications. 
Data were obtained in different settings and registered by 
several doctors, which may lead to variability in laboratory 
parameters and different criteria when interpreting the 
guidelines given by the Registry web.
In spite of these limitations, our work allows a critical 
appraisal of current clinical practice in our country: bone 
density is often overlooked, and when densitometry is 
ordered Z scores are not routinely registered, probably 
because clinicians are more familiar with T scores, less 
useful in these young patients. We are probably missing 
patients with osteoporosis, who could benefit from 
surgery (14, 27). On the other side, localization studies 
before the first surgery are overused.
In conclusion, our results confirm that PHPT is 
usually diagnosed in patients with MEN1 syndrome 
at a young age, and leads to relevant bone and renal 
complications. We can also support that SPTX and TPTX 
are the procedures of choice for PHPT in MEN1. However, 
almost half of the operated patients recurred in the long 
term. Longitudinal and randomized studies are needed to 
establish the best timing for surgery in order to minimize 
the development of chronic bone and renal complications 
as well as the need for reintervention. Recovery from 
hypoparathyroidism years after surgery is not unusual 
in these patients. Even if we had detailed information 
about individual mutations, we cannot confirm previous 
findings that supported a prognostic value of specific 
mutated exons of the MEN1 gene.
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